New drug revealed that eases and suppresses common metabolic disorders
Osteoporosis is a common metabolic disorder and it remains one of the most neglected diseases as the devastating consequences of its development can be drastically improved by targeted molecular therapy. However for all intents and purposes the most interesting aspect of our endeavor were the two research groups simultaneous efforts spearheaded by Prof. Weihong Ma and Dr. Ramil Gorani from the Laboratory of Pharmaceutical Analysis and Drug Design of the National Science Foundation Centre of Excellence for Drug Design Regulatory Analysis and Commercialization (TRANSCARE) of Chinese Academy of Sciences (CAS) to discover a new drug that is capable of reducing the progression of two nephroblastologic disorders at embryonic and neonatal stages without compromising its other absorption parameters.
Osteoporosis is a common metabolic disorder(…)